Hata Akito, Nanjo Shigeki, Otsuka Kyoko, Kida Yoko, Higashi Yoichiro, Kaji Reiko, Fujita Shiro, Katakami Nobuyuki
Dept. of Integrated Oncology, Institute of Biomedical Research and Innovation.
Gan To Kagaku Ryoho. 2009 May;36(5):807-10.
Case one was a 76-year-old woman. She was diagnosed as having lung adenocarcinoma with multiple metastases (cT4N0M1, stage IV, mucinous BAC)in June, 2004. Starting in July, 2004, she received various modalities of chemotherapy( cisplatin+vinorelbine, gefitinib, pemetrexed, gemcitabine, docetaxel, paclitaxel). S-1 monotherapy given to her starting April, 2006 achieved a partial response(PR)as a seventh-line treatment. Case two was a 60-year-old woman. She was diagnosed as having lung adenocarcinoma with multiple metastases(cT4N3M1, stage IV)in October, 2004. That month, her chemotherapy began. After various treatments(cisplatin+vinorelbine, docetaxel, gefitinib), S-1 monotherapy was initiated in February, 2007 as the fourth-line treatment; as a result, PR was achieved. Even though chemotherapies were performed in succession, in the condition of good general status, salvage chemotherapy can be affected by the rotation of drugs. In such cases, S-1 monotherapy can be a reasonable choice from the standpoint of feasibility and effectiveness.
病例一为一名76岁女性。2004年6月,她被诊断为患有肺腺癌伴多发转移(cT4N0M1,IV期,黏液性细支气管肺泡癌)。从2004年7月开始,她接受了多种化疗方案(顺铂+长春瑞滨、吉非替尼、培美曲塞、吉西他滨、多西他赛、紫杉醇)。2006年4月开始给予她S-1单药治疗,作为第七线治疗取得了部分缓解(PR)。病例二为一名60岁女性。2004年10月,她被诊断为患有肺腺癌伴多发转移(cT4N3M1,IV期)。当月,她开始化疗。经过多种治疗(顺铂+长春瑞滨、多西他赛、吉非替尼)后,2007年2月开始给予S-1单药治疗作为第四线治疗;结果,取得了部分缓解。尽管连续进行了化疗,但在一般状况良好的情况下,挽救性化疗可能会受到药物轮换的影响。在这种情况下,从可行性和有效性的角度来看,S-1单药治疗可能是一个合理的选择。